HRP20030338B1 - Inhalative solution formulation containing a titropium salt - Google Patents

Inhalative solution formulation containing a titropium salt

Info

Publication number
HRP20030338B1
HRP20030338B1 HR20030338A HRP20030338A HRP20030338B1 HR P20030338 B1 HRP20030338 B1 HR P20030338B1 HR 20030338 A HR20030338 A HR 20030338A HR P20030338 A HRP20030338 A HR P20030338A HR P20030338 B1 HRP20030338 B1 HR P20030338B1
Authority
HR
Croatia
Prior art keywords
salt
pharmacologically acceptable
titropium
formulation containing
solution formulation
Prior art date
Application number
HR20030338A
Other languages
English (en)
Croatian (hr)
Inventor
Niklaus-Humke Barbara
Schmelzer Christel
Barth Petra
Drechsel Karin
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co. Kg.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma Gmbh & Co. Kg. filed Critical Boehringer Ingelheim Pharma Gmbh & Co. Kg.
Publication of HRP20030338A2 publication Critical patent/HRP20030338A2/hr
Publication of HRP20030338B1 publication Critical patent/HRP20030338B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
HR20030338A 2000-10-31 2001-10-24 Inhalative solution formulation containing a titropium salt HRP20030338B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10054036 2000-10-31
PCT/EP2001/012292 WO2002036104A2 (de) 2000-10-31 2001-10-24 Inhalative lösungsformulierung mit einem tiotropiumsalz

Publications (2)

Publication Number Publication Date
HRP20030338A2 HRP20030338A2 (en) 2005-04-30
HRP20030338B1 true HRP20030338B1 (en) 2011-09-30

Family

ID=7661723

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030338A HRP20030338B1 (en) 2000-10-31 2001-10-24 Inhalative solution formulation containing a titropium salt

Country Status (38)

Country Link
EP (2) EP1333819B1 (cs)
JP (1) JP4344135B2 (cs)
KR (1) KR100853107B1 (cs)
CN (2) CN100396285C (cs)
AR (1) AR038764A1 (cs)
AT (1) ATE373473T1 (cs)
AU (2) AU2173802A (cs)
BG (1) BG66315B1 (cs)
BR (1) BRPI0115076B8 (cs)
CA (1) CA2426074C (cs)
CY (1) CY1107825T1 (cs)
CZ (1) CZ300794B6 (cs)
DE (2) DE50113037D1 (cs)
DK (1) DK1333819T3 (cs)
EA (1) EA007604B1 (cs)
EC (1) ECSP034541A (cs)
EE (1) EE05314B1 (cs)
ES (1) ES2294045T3 (cs)
HR (1) HRP20030338B1 (cs)
HU (1) HU229411B1 (cs)
IL (2) IL155538A0 (cs)
ME (1) ME00244B (cs)
MX (1) MXPA03003742A (cs)
MY (1) MY138940A (cs)
NO (1) NO332519B1 (cs)
NZ (1) NZ526023A (cs)
PE (1) PE20030092A1 (cs)
PL (1) PL203316B1 (cs)
PT (1) PT1333819E (cs)
RS (1) RS50859B (cs)
SA (1) SA01220482B1 (cs)
SI (1) SI1333819T1 (cs)
SK (1) SK286027B6 (cs)
TW (1) TWI293885B (cs)
UA (1) UA78690C2 (cs)
UY (1) UY26989A1 (cs)
WO (1) WO2002036104A2 (cs)
ZA (1) ZA200302922B (cs)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10216036A1 (de) * 2002-04-11 2003-10-23 Boehringer Ingelheim Pharma Aerosolformulierung für die Inhalation enthaltend ein Tiotropiumsalz
CN1292748C (zh) * 2003-03-05 2007-01-03 南昌弘益科技有限公司 噻托溴铵吸入粉雾剂及其制备工艺
CA2544357A1 (en) * 2003-11-03 2005-05-12 Boehringer Ingelheim International Gmbh Tiotropium salts, methods for the production thereof, and pharmaceutical formulations containing the same
EP2067779B9 (de) * 2003-11-03 2013-10-16 Boehringer Ingelheim International GmbH Tiotropiumsalze, Verfahren zu deren Herstellung und Arzneimittelformulierungen diese enthaltend
EP1881980B1 (en) 2005-05-02 2012-08-22 Boehringer Ingelheim International GmbH Novel crystalline forms of tiotropium bromide
EP2044967A1 (de) * 2007-10-01 2009-04-08 Boehringer Ingelheim Pharma GmbH & Co. KG Zerstäuber
CN104306361A (zh) * 2014-09-24 2015-01-28 万特制药(海南)有限公司 一种含噻托溴铵的吸入性溶液
CN111374963A (zh) * 2018-12-31 2020-07-07 天津药业研究院有限公司 一种用于吸入的噻托铵溶液剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027959A2 (de) * 1996-12-20 1998-07-02 Boehringer Ingelheim Pharma Kg Neue wässerige arzneimittelzubereitungen zur erzeugung treibgasfreier aerosole
WO2000023037A1 (de) * 1998-10-17 2000-04-27 Boehringer Ingelheim Pharma Kg Zweikammer-kartusche für vernebler

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3931041C2 (de) * 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
SG45171A1 (en) * 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
DE19536902A1 (de) * 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027959A2 (de) * 1996-12-20 1998-07-02 Boehringer Ingelheim Pharma Kg Neue wässerige arzneimittelzubereitungen zur erzeugung treibgasfreier aerosole
WO2000023037A1 (de) * 1998-10-17 2000-04-27 Boehringer Ingelheim Pharma Kg Zweikammer-kartusche für vernebler

Also Published As

Publication number Publication date
MXPA03003742A (es) 2004-10-15
PL360405A1 (en) 2004-09-06
NO20031911D0 (no) 2003-04-29
AU2002221738B2 (en) 2007-01-11
IL155538A0 (en) 2003-11-23
JP2004512357A (ja) 2004-04-22
CN100396285C (zh) 2008-06-25
ATE373473T1 (de) 2007-10-15
NZ526023A (en) 2005-05-27
BG107727A (bg) 2004-11-30
EA200300482A1 (ru) 2003-12-25
MY138940A (en) 2009-08-28
NO20031911L (no) 2003-04-29
SI1333819T1 (sl) 2007-12-31
WO2002036104A2 (de) 2002-05-10
PL203316B1 (pl) 2009-09-30
ES2294045T3 (es) 2008-04-01
DK1333819T3 (da) 2007-12-03
YU33003A (sh) 2006-05-25
BR0115076A (pt) 2003-07-29
AR038764A1 (es) 2005-01-26
TWI293885B (en) 2008-03-01
BRPI0115076B1 (pt) 2016-07-26
DE10152521A1 (de) 2002-07-11
HUP0301378A2 (hu) 2003-10-28
EP1333819A2 (de) 2003-08-13
MEP40408A (en) 2011-02-10
DE50113037D1 (de) 2007-10-31
EP1333819B1 (de) 2007-09-19
UY26989A1 (es) 2002-06-20
CZ20031486A3 (cs) 2003-08-13
EP1837021A2 (de) 2007-09-26
HU229411B1 (en) 2013-12-30
CN101292964A (zh) 2008-10-29
HRP20030338A2 (en) 2005-04-30
EP1837021A3 (de) 2008-03-19
JP4344135B2 (ja) 2009-10-14
ZA200302922B (en) 2004-04-22
PE20030092A1 (es) 2003-03-24
EA007604B1 (ru) 2006-12-29
ECSP034541A (es) 2003-05-26
NO332519B1 (no) 2012-10-08
SK5272003A3 (en) 2003-10-07
HK1060524A1 (zh) 2004-08-13
IL155538A (en) 2008-11-26
WO2002036104A3 (de) 2002-08-01
CN1473038A (zh) 2004-02-04
KR100853107B1 (ko) 2008-08-21
ME00244B (me) 2011-05-10
CY1107825T1 (el) 2013-06-19
SA01220482B1 (ar) 2007-07-31
SK286027B6 (sk) 2008-01-07
UA78690C2 (uk) 2007-04-25
BRPI0115076B8 (pt) 2021-05-25
AU2173802A (en) 2002-05-15
RS50859B (sr) 2010-08-31
BG66315B1 (bg) 2013-04-30
CA2426074C (en) 2008-12-23
CA2426074A1 (en) 2002-05-10
EE200300203A (et) 2003-10-15
EE05314B1 (et) 2010-08-16
CZ300794B6 (cs) 2009-08-12
PT1333819E (pt) 2007-10-29
HUP0301378A3 (en) 2005-12-28
KR20030060926A (ko) 2003-07-16

Similar Documents

Publication Publication Date Title
CO5271759A1 (es) Formulacion en solucion que contiene una mezcla de disolventes
ES2599973T3 (es) Una formulación tópica de propionato de clobetasol de nivel bajo para tratar trastornos de la membrana mucosa y de la piel
EA008005B1 (ru) Интраназальный препарат ротиготина
KR19980081238A (ko) 약학 제형
JP2012520882A5 (cs)
Cho et al. Formulation and evaluation of ondansetron nasal delivery systems
KR102718482B1 (ko) 디쿠아포솔을 포함하는 점안 조성물
US20020119997A1 (en) Nimesulide gel systems for topical use
KR20190075956A (ko) 에피나스틴 함유 점안액
HRP20030338B1 (en) Inhalative solution formulation containing a titropium salt
IL162496A0 (en) Pharmaceutical compositions containing cyclosporin
JPH0463852B2 (cs)
JPH06145044A (ja) 人工唾液
BR0116060A (pt) Composição farmacêutica de dronedarona para administração parenteral
PT1414467E (pt) Tratamento topico da mastalgia
CA2494473A1 (en) Stabilized protein compositions for topical administration and methods of making same
JP4393552B2 (ja) ピリドンカルボン酸誘導体を含有するローション剤
US20220249470A1 (en) Treatment of skin disorders by topical administration of vegf inhibitors
CN116437910A (zh) 含有西替利嗪和托可索仑的眼用组合物
WO2021216450A8 (en) Opioid antagonist formulations
JPH0717863A (ja) プラノプロフェン点眼液
KR100791871B1 (ko) 방부제
JP4524559B2 (ja) 眼科用組成物及びビタミンａ類の安定化方法
KR101690765B1 (ko) 항진균성 활성물질을 포함하는 경피 제제
EP3908255B1 (en) Stable topical compositions of fenoldopam

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20191003

Year of fee payment: 19

ODRP Renewal fee for the maintenance of a patent

Payment date: 20201020

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20211024